Familial hypercholesterolemia: Review article;Hipercolesterolemia familiar: Artículo de revisión

Revista Colombiana de Cardiologia

Volumn 23, Issue , 2016, Pages 4-26

  Merchán, Alonso ^a   Ruiz, Álvaro J ^b   Campo, Rafael ^c   Prada, Carlos E ^c   Toro, Juan M ^d   Sánchez, Robinson ^c   Gómez, Juan E ^e   Jaramillo, Nicolás I ^f   Molina, Dora I ^g   Vargas Uricoechea, Hernando ^h   Sixto, Sherien ⁱ   Castro, Javier M ^c   Quintero, Adalberto E ^j   Coll, Mauricio ^k   Slotkus, Stase ^a   Ramírez, Andrés ^l   Pachajoa, Harry ^l   Ávila, Fernando A ^l   Alonso K, Rodrigo ^m  

^a Fundacion Clinica Shaio   (Colombia)

^b PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^c FUNDACIÓN CARDIOVASCULAR DE COLOMBIA   (Colombia)

^d HOSPITAL PABLO TOBÓN URIBE   (Colombia)

^e FUNDACIÓN VALLE DEL LILI   (Colombia)

^f UNIVERSIDAD CES   (Colombia)

^g Clinical Research Association   (Colombia)

^h UNIVERSIDAD DEL CAUCA   (Colombia)

ⁱ Servicio de rehabilitación cardiaca Instituto del Corazón de Bucaramanga   (Colombia)

^j Centro de investigaciones Fundación del Caribe para la Investigación Biomédica   (Colombia)

^k UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^l UNIVERSIDAD ICESI   (Colombia)

^m CLÍNICA LAS CONDES   (Chile)

more..

Author keywords

Familial hypercholesterolemia; LDL cholesterol

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CHOLESTEROL BLOOD LEVEL; DIAGNOSTIC ERROR; DISEASE SEVERITY; FAMILIAL HYPERCHOLESTEROLEMIA; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LIFESTYLE MODIFICATION; PREVALENCE;

EID: 84975217721     PISSN: 01205633     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rccar.2016.05.002     Document Type: Article

References (191)

1. World Health Organization. World Health Statistics 2012. Disponible en: . http://www.who.int/gho/publication/world-%20health-statistics/2012/en/9.
2. Mata P., Alonso R., González-Juanatey J.R., Badimón L., Díaz-Díaz J.L., Muñoz M.T., et al. Diagnóstico y tratamiento de la hipercolesterolemia familiar en España. Documento de consenso. Aten Primaria. 2015, 47:56-65.
3. Ascaso J.F., Mata P., Arbona C., Civeira F., Valdivieso P., Masana L. Hipercolesterolemia familiar homocigótica: adaptación a España del documento de posición del grupo de consenso sobre hipercolesterolemia familiar de la Sociedad Europea de Arteriosclerosis. Documento de Consenso de la Sociedad Española de Arteriosclerosis (SEA) y la Fundación Hipercolesterolemia Familiar (FHF). Clin Invest Arterioscl. 2015, 27:80-96.
4. Bouhairie V.E., Goldberg A.C. Familial hypercholesterolemia. Cardiol Clin. 2015, 33:169-179.
5. Vallejo-Vaz A.J., Kondarally S.R., Cole D., Hovingh G.K., Kastelein J., Mata P., Santos R.D., et al. Familial hypercholesterolaemia: a call to arms. Atherosclerosis. 2015, 243:257-259.
6. Gidding S., Champagne M.A., Ferranti S.D., Defesche J., Ito M.K., Knowles J., et al. The agenda for familial hypercholesterolaemia. A scientific statement from the American Heart Association. Circulation. 2015, 132. 00-00.
7. Weigman A., Gidding S.S., Watts G.F., Chapman M.J., Ginsberg H.N., Cuchel M., et al. Familial hypercholesterolemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015, 36:2425-2437.
8. Watts G.F., Gidding S., Wierzbicki A.S., Toth P.P., Alonso R., Brown W.V., et al. Integrated guidance on the care of familial hypercholesterolemia from the International Familial Hypercholesterolemia Foundation. Int J Cardiol. 2014, 171:309-325.
9. Cuchel M., Bruckert E., Ginsberg H.N., Raal F.J., Santos R.D., Hegele R.A., et al. Homozigous familial hipercolesterolemia: new insights and guidance for clinicians to improve detection and clinical Management. A position paper from the Consensus Panel on Familial Hypercholesterolemia of the European Atherosclerosis Society. Eur Hear J. 2014, 35:2146-2157.
10. Elikir G., Cúneo C., Lorenzatti A., Schreier L., Corral P., Aimone D., et al. Consenso de la Sociedad Argentina de lípidos sobre hipercolesterolemia familiar. Sociedad Argentina de Lípidos. 2014, 1-51.
11. Sniderman A., Tsimikas S., Fazio S. The severe hypercholesterolemia phenotype. Clinical diagnosis, management, and emerging therapies. J Am Coll Cardiol. 2014, 63:1935-1947.
12. Hovingh G.K., Davidson M.H., Kasyelein J., O'Connor A.M. Diagnosis and treatment of familial hypercholesterolaemia. Eur Heart J. 2013, 34:962-971.
13. Austin M., Hutter C.M., Zimmern R.L., Humphries S.S. Genetic causes of monogenic heterozigous familial hipercolesterolemia. Am J Epidemiol. 2004, 160:407-420.
14. Sniderman A.D., Tsimikas S., Fazio S. The severe hipercolesterolemia phenotype. J Am Coll Cardiol. 2014, 63:1935-1947.
15. Lambert G., Sjouke B., Choque B., Kastelein J., Hovingh K. The PCSK9 decade. J Lipid Res. 2012, 53:2515-2524.
16. Nordestgaard B.G., Chapman M.J., Humphries S.E., Ginsberg H.J., Masana L., Descamps O.S., et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013, 34:3478-3490.
17. William R.R., Hunt S.C., Schumacher M.C., Hegele R.A., Leppert M., Ludwig E.H., et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics (MEDPED). Am J Cardiol. 1993, 72:171-176.
18. Risk of fatal coronary heart disease in familial hipercolesterolemia. (Simon Broome). BMJ. 1991, 303:893-896. Scientific Steering Committee of the Simon Broome Register Group.
19. Civeira F. International Panel on Management of Familial Hypercholesterolemia. Guidelines for the diagnosis and Management of heterozygous familial hipercolesterolemia. (Dutch Lipid Clinic Network). Atherosclerosis 2004, 173:55-68.
20. Alonso R., Andres E., Mata E., Fuentes-Jimenez F., Badimon L., Lopez-Miranda J., et al. Lipoprotein(a) levels in familial hypercholesterolaemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. J Am Coll Cardiol. 2014, 63:1982-1989.
21. Watts G.F., Juniper A., Bockxmeer F., Ademi Z., Liew D., O'Leary P. Familial Hypercholesterolemia: a review with emphasis on evidence for treatment, new models of care and health economic evaluations. Int J Evidence Health 2012, 10:211-221.
22. Hobbs H.H., Russell D.W., Brown M.S., Goldstein J.L. The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Annual Review of Genetics 1990, 24:133-170.
23. Kolansky D.M., Cuchel M., Clark B.J., Paridon S., McCrindle B.W., Wiegers S.E., et al. Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia. Am J. Cardiol. 2008, 102:1438-1443.
24. Moorjani S., Torres A., Gagn C., Brun D., Lupien P., Roy M., et al. Mutations of low-density-lipoprotein-receptor gene, variation in plasma cholesterol, and expression of coronary heart disease in homozygous familial hypercholesterolaemia. Lancet. 1993, 341:1303-1306.
25. Francke U., Brown M.S., Goldstein J.L. Assignment of the human gene for the low density lipoprotein receptor to chromosome 19: synteny of a receptor, a ligand, and a genetic disease. Proc Natl Acad Sci USA. 1984, 81:2826-2830.
26. Leigh S.E., Foster A.H., Wittall R.A., Hubbart C.S., Humphries S.E. Update and analysis of the University College London low density lipoprotein receptor familial hypercholesterolemia database. Ann Hum Genet. 2008, 72:485-498.
27. Innerarity T.L., Weisgraber K.H., Arnold K.S., Mahley R.W., Kraus R.M., Vega G.L., Grundy S.M. Familial defective apolipoprotein B-100: low density lipoprotein with abnormal receptor binding. Proc Natl Acad Sci USA. 1987, 84:6919-6923.
28. Abifadel M., Varret M., Rabes J.P., Allard D., Ouguerram K., Devillers M., et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nature Genetics. 2003, 34:154-156.
29. Cohen J.C., Boerwinkle E., Mosley T.H., Hobbs H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. New Engl J Med. 2006, 354:1264-1272.
30. Garcia C.K., Wilund K., Arca M., Zuliani G., Fellin R., Maioli M., Calandra S., et al. Autosomal recesive hipercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science. 2001, 292:1394-1398.
31. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-21.
32. Hanukoglu I. Steroidogenic enzymes: structure, function, and role in regulation of steroid hormone biosynthesis. J Steroid Biochem Mol Biol. 1992, 43(8):779-804.
33. Goldstein J.L., Brown M.S. The cholesterol quartet. Science 2001, 292:1310-1322.
34. Pearse B.M. Clathrin: a unique protein associated with intracellular transfer of membrane by coated vesicles». Proceedings of the National Academy of Sciences of the United States of America 1976, 73(4):1255-1259.
35. Raal F.J., Santos R.D. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis. 2012, 223(2):262-268.
36. Gagné C., Moorjani S., Brun D., Toussaint M., Lupien P.J. Heterozygous familial hypercholesterolemia. Atherosclerosis. 1979, 34:13-24.
37. Myant N.B. Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolaemia. Atherosclerosis. 1993, 104:1-18.
38. Zhao Z., Tuakli-Wosornu Y., Lagace T.A., Kinch L., Grishin N.V., Horton J.D., et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet. 2006, 79:514-523.
39. Goldstein J.L., Hobbs H.H., Brown M.S. Familial hypercholesterolemia. The metabolic basis of inherited disease 2001, 120:2863-2913. McGraw-Hill, New York.
40. Brown M.S., Goldstein J.L. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986, 232:34-47.
41. Marks D., Thorogood M., Neil H.A., Humphries S.E. A review on the diagnosis, natural history and treatment of familial hipercolesterolemia. Atherosclerosis. 2003, 168:1-14.
42. Nordestgaard B.G., Chapman M.J., Humphries S.E., Ginsberg H.N., Masana L., Descamps O.S., et al. Familial hipercolesterolemia is underdiagnosed and undertreated in the general population. Consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013, 34:3478-3490.
43. Lahtinen A.M., Havulinna A.S., Jula A., Salomaa V., Kontula K. Prevalence and clinical correlates of familial hypercholesterolemia founder mutations in the general population. Atherosclerosis. 2015, 238:64-69.
44. Steyn K., Goldberg Y.P., Kotze M.J., Steyn M., Swanepoel A.S.P., Fourie J.M., et al. Estimation of the prevalence of familial hypercholesterolaemia in a rural Afrikaner community by direct screening for three Afrikaner founder low density lipoprotein receptor gene mutations. Hum Genet. 1996, 98:479.
45. Knowles J.D., O'Brien E.C., Greendale K. Reducing the burden of disease and death from familial hypercholesterolemia: A call to action. Am Heart J. 2014, 168:807-811.
46. Stary H.C. Evolution and progession of atheroclerotic lesions in coronary arteries of children and Young adults. Arteriosclerosis. 1989, 9:119-123.
47. De Jongh S., Lilien M.R., Stroes E.S., Baker H.D., Kastelein J.J. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol. 2002, 40:2117-2121.
48. Benlian P., Turquet A., Carrat F., Amsellem S., Sanchez L., Briffaut D.G.J.P. Diagnosis scoring for clinical identification of children with heterozygous familial hypercholesterolemia. J Pediat Gastroenterol Nutr. 2009, 48:456-463.
49. Daniels S.R., Greer F.R. Lipid screening and cardiovascular health in childhood. Pediatrics. 2008, 122:198-208.
50. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011, 128:S213-S256.
51. Muñoz O., García A., Fernández D., Higuera A., Ruiz A., Aschner P., Merchán A. Guía de práctica clínica para la prevención, detección temprana, diagnóstico, tratamiento y seguimiento de las dislipidemias en la población mayor de 18 años. Act Med Colomb. 2014, 39(supl 2):5-29.
52. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011, 128:S213-S256.
53. Havekes L., de Wit E., Leuven J.G., Klasen E., Utermann G., Weber W., et al. Apolipoprotein E3 - Leiden. A new variant of human apolipoprotein E associated with familial type III hyperlipoproteinemia. Hum Genet. 1986, 73(2):157-163.
54. Schaefer J.R. Unraveling hyperlipidemia type III (dysbetalipoproteinemia), slowly. Eur. J Hum Genet 2009, 17(5):541-542.
55. Fung M., Hill J., Cook D., Frohlich J. Case series of type III hyperlipoproteinemia in children. BMJ. 2011.
56. Mahley R.W., Huang Y., Rall S.C. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. J Lipid Res. 1999, 40(11):1933-1949.
57. Moghadasian M.H., Salen G., Frohlich J.J., Scudamore C.H. Cerebrotendinous xanthomatosis: a rare disease with diverse manifestations. Arch Neurol. 2002, 59:527-529.
58. Berginer V.M., Abeliovich D. Genetics of cerebrotendinous xanthomatosis (CTX): an autosomal recessive trait with high gene frequency in Sephardim of Moroccanorigin. Am J Med Genet. 1981, 10(2):151-157.
59. Verrips A., Nijeholt G.J., Barkhof F., Van Engelen B.G., Wesseling P., Luyten J.A., et al. Spinal xanthomatosis: a variant of cerebrotendinous xanthomatosis. Brain. 1999, 122:1589-1595.
60. Berginer V.M., Salen G., Shefer S. Long - term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid. N Engl J Med. 1984, 311(26):1649-1652.
61. Huigen R., Stork A.D., Defesche J.C., Peter J., Alonso R., Cuevas A., Kastelein J.J., et al. Extreme xanthomatosis in patients with both familial hypercholesterolemia and cerebrotendineous xanthomatosis. Clin Genet. 2012, 81:24-28.
62. Berge K.E., Tian H., Graf G.A., Yu L., Grishin N.V., Schultz J., et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science. 2000, 290(5497):1771-1775.
63. Nguyen L.B., Shefer S., Salen G., Ness G.C., Tint G.S., Zaki F.G., Rani I. A molecular defect in hepatic cholesterol biosynthesis in sitosterolemia with xanthomatosis. J Clin Invest. 1990, 86(3):923-931.
64. Salen G., Shefer S., Batta A.K., Tint G.S., Xu G., Honda A. Abnormal cholesterol biosynthesis in sitosterolaemia and the Smith - Lemli - Opitz syndrome. J Inherit Metab Dis. 1996, 19(4):391-400.
65. Perk J., De Backer G., Gohlke H., Graham I., Reiner Z., Verschuren W.M.M., et al. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Atherosclerosis. 2012, 223:1-68.
66. Vuorio A., Docherty K.F., Humphries S.E., Kuoppala J., Kovanen P.T. Statin treatment of children with familial hypercholesterolemia--trying to balance incomplete evidence of long-term safety and clinical accountability: are we approaching a consensus?. Atherosclerosis. 2013, 6(2):315-320.
67. Lorenz M.W., Markus H.S., Bots M.L., Rosvall M., Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007, 115(4):459-467.
68. Nambi V., Chambless L., Folsom A.R., He M., Hu Y., Mosley T., et al. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. J Am Coll Cardiol. 2010, 55(15):1600-1607.
69. Bots M.L., Hofman A., De Jong P.T., Grobber D.E. Common carotid intima-media thicknes as an indicator of atherosclerosis at other sites of the carotid artery. The Rotterdam study. Ann Epidemiol. 1996, 6:147-153.
70. Engelen L., Ferreira I., Stehouwer C.D., Boutouyrie P., Laurent S. Reference intervals for common carotid intima-media thickness measured with echo tracking: relation with risk factors. Eur Heart J. 2013, 34(30):2368-2380. Reference Values for Arterial Measurements Collaboration.
71. Kusters D.M., Wiegman A., Kstelein J.J., Hutten B.A. Carotid intima-media thickness in children with familial hypercholesterolemia. Circ Res. 2014, 114:307-310.
72. Den Ruijter H.M., Peters S.A.E., Anderson T.J., Britton A.R., Dekker J.M., Eijkemans M.J., et al. Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. JAMA. 2012, 308(8):796-803.
73. Greenland P., Bonow R.O., Brundage B.H., Budoff M.J., Eisenberg M.J., Grundy S.M., et al. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography) developed in collaboration with the Society of Atherosclerosis Imaging and Prevention and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol. 2007, 49(3):378-402.
74. Santos R.D., Miname M.H., Martinez L.R.C., Rochitte C.E., Chacra A.P.M., Nakandakare E.R., et al. Non-invasive detection of aortic and coronary atherosclerosis in homozygous familial hypercholesterolemia by 64 slice multi-detector row computed tomography angiography. Atherosclerosis. 2008, 197(2):910-915.
75. Yeboah J., McClelland R.L., Polonsky T.S., Burke G.L., Sibley C.T., O'Leary D., et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA. 2012, 308(8):788-795.
76. Miname M.H., Ribeiro M.S., Parga Filho J., Avila L.F., Bortolotto L.A., Martinez L.R.C., et al. Evaluation of subclinical atherosclerosis by computed tomography coronary angiography and its association with risk factors in familial hypercholesterolemia. Atherosclerosis. 2010, 213(2):486-491.
77. Caballero P., Alonso R., Rosado P., Mata N., Fernandez-Fijera L., Jimenez-Borregero J.L., et al. Detection of subclinical atherosclerosis in familial hypercholesterolemia using non-invasive imaging modalities. Atherosclerosis. 2012, 222:468-472.
78. Kim W.Y., Stuber M., Börnert P., Kissinger K.V., Manning W.J., Botnar R.M. Three-dimensional black-blood cardiac magnetic resonance coronary vessel wall imaging detects positive arterial remodeling in patients with nonsignificant coronary artery disease. Circulation. 2002, 106(3):296-299.
79. Kolansky D.M., Cuchel M., Clark B.J., Paridon S., McCrindle B.W., Wiegers S.E., et al. Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia. Am J Cardiol. 2008, 102(11):1438-1443.
80. Koh T.W. Aortic root involvement in homozygous familial hypercholesterolemia. Transesophageal echocardiographic appearances of supravalvular aortic stenosis. Echocardiogr Mt Kisco N. 2005, 22(10):859-860.
81. Greenland P., Alpert J.S., Beller G.A., Benjamin E.J., Budoff M.J., Fayad Z.A., et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: executive summary: a report of the American College of Cardiology Foundation/American Heart Association. Task Force on Practice Guidelines. Circulation 2010, 122(25):2748-2764.
82. Fowkes F.G.R., Price J.F., Stewart M.C.W., Butcher I., Leng G.C., Pell A.C.H., et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010, 303(9):841-848.
83. Stone N.J., Robinson J., Lichtenstein A.H., Bairey Merz C.N., Lloyd-Jones D.M., Blum C.B., et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013, 63:2889-2934.
84. Catapano A.L., Reiner Z., De Baker G., Graham I., Taskinen M.R., Wiklund D., et al. ESC/EAS guidelines for the management of dyslipidaemias. Atherosclerosis 2011, 217S:S1-S44.
85. Jacobson T.A., Iko M.K., Maki K.C., Orringer C.E., Bays H.E., Jones P.H., et al. National Lipid Association recomendations for patient-centered management of dyslididemia: Part 1-full report. J Clinic Lipidol. 2015, 9:129-169.
86. Jacobson T.A., Maki K.C., Orringer C., Jones P., Kris-Ettherton P., Sikand G., et al. National Lipid Association Recomendations for patient-Centered management of dslipidemia: Part 2. J Clinic Lipidol. 2015, En prensa.
87. Pijlman A.H., Huijgen R., Verhagen S.N., Imholz B.P., Liem A.H., Kastelein J.J., et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: A large cross-sectional study in The Netherlands. Atherosclerosis. 2010, 209:189-194.
88. Mata N., Alonso R., Badimón L., Padró T., Fuentes F., Muñiz O., et al. Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART). Lipids Health Dis. 2011, 10:94.
89. Jansen A.C., van Aalst-Cohen E.S., Tanck M.W., Trip M.D., Lansberg P.J., Liem A.H., et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med. 2004, 256(6):482-490.
90. Sauvage Nolting P.R., Defesche J.C., Buirma R.J., Hutten B.A., Lansberg P.J., Kastelein J.J. Prevalence and significance of cardiovascular risk factors in a large cohort of patients with familial hypercholesterolaemia. J Intern Med. 2003, 253:161-168.
91. Kamstrup P.R., Tybjaerg-Hansen A., Steffensen R., Nordestgaard B.G. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009, 301:2331-2339.
92. Nordestgaard B.G., Chapman M.J., Ray K., Boren J., Andreotti F., Watts G.F., et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010, 31:2844-2853.
93. Neil A., Cooper J., Betteridge J., Capps N., McDowell I., Durrington P., et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J. 2008, 29:2625-2633.
94. Versmissen J., Oosterveer D.M., Yazdanpanah M., Defesche J.C., Basart D.C.G., Liem A.H., et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ. 2008, 337:a2423.
95. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4 S). Lancet 1994, 344:1383-1389.
96. Shepherd J., Cobbe S.M., Ford I., Isles ChG, Lorimer A.R., Macfarlane P.W., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995, 333:1301-1308. West of Scotland Coronary Prevention Study Group.
97. The Lipid Research Clinics Coronary Primary Prevention Trial results. Reduction in incidence of coronary heart disease. JAMA. 1984, 251:351-364.
98. Raal F.J., Pappu A.S., Illingworth D.R., Pilcher G.J., Marais A.D., Firth J.C., et al. Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolemia. Atherosclerosis. 2000, 150:421-428.
99. Marais A.D., Raal F.J., Stein E.A., Rader D.J., Blasetto J., Palmer M., Wilpshaarf W. A dose titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolemia. Atherosclerosis. 2008, 197:400-406.
100. Raal F.J., Pilcher G.J., Panz V.R., Van Deventer H.E., Brice B.C., Blom D.J., et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation. 2011, 124:2202-2207.
101. Doble inhibición del colesterol: papel de la regulación intestinal y hepática. Rev Esp Cardiol. Supl. 2006, 6(G):52-62.
102. Pisciotta L., Fasano T., Bellocchio A., Bocchi L., Sallo R., Fresa R., et al. Effect of ezetimibe coadministered with statins in genotype-confirmed heterozygous FH patients. Atherosclerosis. 2007, 194:e116-e122.
103. Van der Graaf A., Cuffie-Jackson C., Vissers M.N., Trip M.D., Gagné C., Shi G., et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J Am Coll Cardiol. 2008, 52:1421-1429.
104. Gagne C., Gaudet D., Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation. 2002, 105:2469-2475. for the Ezetimibe Study Group.
105. Knapp H.H., Schrott H., Ma P., Knopp R., Chin B., Gaziano J.M., et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med. 2001, 110:352-360.
106. Insull W. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J. 2006, 99:257-273.
107. Ito M., McGowan M., Moriarty P. National Lipid Association Expert Panel on Familial Hypercholesterolemia. Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011, 5:S38-S45.
108. Vuorio A., Tikkanen M.J., Kovanen P.T. Inhibition of hepatic microsomal triglyceride transfer protein -a novel therapeutic option for treatment of homozygous familial hypercholesterolemia. Vasc Health Risk Manag. 2014, 10:263-270.
109. Cuchel M., Rader D.J. Microsomal transfer protein inhibition in humans. Curr Opin Lipidol. 2013, 24:246-250.
110. Raal F.J. Lomitapide for homozygous familial hypercholesterolaemia. Lancet. 2013, 381:7-8.
111. Geary R.S., Baker B.F., Crooke S.T. Clinical and preclinical pharmacokinetics and pharmacodynamics of mipomersén (Kynamro(®)): a second-generation antisense oligonucleotide inhibitor of apolipoprotein B. Clin Pharmacokinet. 2015, 54:133-146.
112. Rader D.J., Kastelein J.J. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation. 2014, 129:1022-1032.
113. Raal F.J., Santos R.D., Blom D.J., Marais A.D., Charng M.J., Cromwell W.C., et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010, 375:998-1006.
114. McGowan M.P., Tardif J.C., Ceska R., Burgess L.J., Soran H., Gouni-Berthold I., et al. Randomized, placebo-controlled trial of mipomersén in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS One 2012, 7:e49006. 10.1371/journal.pone.0049006.
115. Stein E.A., Dufour R., Gagne C., Gaudet D., East C., Donovan J.M., Chin W., Tribble D.L., McGowan M., Apolipoprotein B. synthesis inhibition with mipomersén in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation. 2012, 126:2283-2292.
116. Thomas G.S., Cromwell W.C., Ali S., Chin W., Flaim J.D., Davidson M. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2013, 62:2178-2184.
117. Santos R.D., Raal F.J., Catapano A.L., Witztum J.L., Steinhagen-Thiessen E., Tsimikas S. Mipomersen, an antisense oligonucleotide to Apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia. Results of 4 phase III Trials. Arterioscler Thromb Vasc Biol. 2015, 35. 00-00.
118. Sjouke B., Hovingh G.K., Kastelein J.J., Stefanutti C. Homozygous autosomal dominant hypercholesterolaemia: prevalence, diagnosis, and current and future treatment perspectives. Curr Opin Lipidol. 2015, 26(3):200-209.
119. Brown W.V., Rader D.J., Goldberg A.C. JCL roundtable: drug treatment of severe forms of familial hypercholesterolemia. J Clin Lipidol. 2014, 8:10-17.
120. Yu R.Z., Grundy J.S., Geary R.S. Clinical pharmacokinetics of second generation antisense oligonucleotides. Expert Opin Drug Metab Toxicol. 2013, 9:169-182.
121. Joseph L, Robinson JG. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy. Prog Cardiovasc Dis. 2015;pii:S0033-0620(15)00029-8. doi: 10.1016/j.pcad.2015.04.004.[Epub ahead of print].
122. Catapano A.L., Papadopoulos N. The safety of therapeutic monoclonal antibodies: Implications for cardiovascular disease and targeting the PCSK9 pathway. Atherosclerosis. 2013, 228:18-28.
123. Roth E.M., Diller P. Alirocumab for hyperlipidemia: physiology of PCSK9 inhibition, pharmacodynamics and Phase I and II clinical trial results of a PCSK9 monoclonal antibody. Future. Cardiol. 2014, 10:183-199.
124. McKenney J.M., Koren M.J., Kereiakes D.J., Hanotin C., Ferrand A.-C., Stein E.A. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012, 59:2344-2353.
125. Roth E.M., McKenney J.M., Hanotin C., Asset G., Stein E.A. Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia. N Engl J Med. 2012, 367:1891-1900.
126. Stein E.A., Gipe D., Bergeron J., Gaudet D., Weiss R., Dufour R., Wu R., Pordy R. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012, 380:29-36.
127. Stein E.A., Mellis S., Yancopoulos G.D., Stahl N., Logan D., Smith W.B., Lisbon E., Gutierrez M., Webb C., Wu R., Du Y., Kranz T., Gasparino E., Swergold G.D. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med. 2012, 366:1108-1118.
128. Roth E.M., Taskinen M.R., Ginsberg H.N., Kastelein J.J., Colhoun H.M., Robinson J.G., Merlet L., Pordy R., Baccara-Dinet M.T. Monotherapy with the PCSK9 inhibitor Alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24 week, double-blind, randomized Phase 3 trial. Int J Cardiol. 2014, 176:55-61.
129. Robinson J.G., Farnier M., Krempf M., Berbern J., Luc G., Averna M., et al. Effficacy and safety of alirocumab in reducing lipids and cardiovascular events. Odyssey Long-Term Investigators. N Engl J Med. 2015, 372:1489-1499.
130. Verbeek R, Stoekenbroek RM, Kees Hovingh G. PCSK9 inhibitors: Novel therapeutic agents for the treatment of hypercholesterolemia. Eur J Pharmacol. 2015, May 16. pii: S0014-2999(15)00464-1. doi: 10.1016/j.ejphar.2015.03.099.[Epub ahead of print].
131. Koren M.J., Lundqvist P., Bolognese M., Neutel J.M., Monsalvo M.L., Yang J., Kim J.B., Scott R., Wasserman S.M., Bays H. MENDEL-2 Investigators. Anti-PCSK9 monotherapy for hypercholesterolemia: theMENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol. 2014, 63:2531-2540.
132. Raal F.J., Stein E.A., Dufour R., Turner T., Civeira F., Burgess L., et al. RUTHERFORD-2 Investigators. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 2015, 385:331-340.
133. Robinson J.G., Nedergaard B.S., Rogers W.J., Fialkow J., Neutel J.M., Ramstad D., et al. LAPLACE-2 Investigators. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA 2014, 311:1870-1882.
134. Stroes E, Colquhoun D, Sullivan D, Civeira F, Rosenson RS, Watts GF, et al. GAUSS-2 Investigators. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 201417;63:2541-8.
135. Blom D.J., Hala T., Bolognese M., Lillestol M.J., Toth P.D., Burgess L., et al. DESCARTES Investigators. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014, 370:1809-1819.
136. Hassan M., Yacoub M. GAUSS-2, RUTHERFORD-2, LAPLACE-2, DESCARTES, and TESLA Part B: PCSK9 inhibitors gain momentum. Glob Cardiol Sci Pract. 2014, (4):360-366.
137. Huynh K. Dyslipidaemia: Assessing the efficacy and safety of evolocumab and Alirocumab. Nat Rev Cardiol. 2015, 12:261.
138. Sabatine M.S., Giugliano R.P., Wiviott S.D., Raal F.J., Blom D.J., Robinson J., et al. Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015, 372:1500-1509.
139. Ballantyne C.M., Neutel J., Cropp A., Duggan W., Wang E.Q., Plowchalk D., et al. Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia. Am J Cardiol. 2015, 115:1212-1221.
140. Desai NR, Sabatine MS. PCSK9 inhibition in patients with hypercholesterolemia. Trends Cardiovasc Med. 2015 Feb 11. pii: S1050-1738(15)00030-4. doi: 10.1016/j.tcm.2015.01.009.[Epub ahead of print].
141. Page M.M., Watts G.F. Emerging PCSK9 inhibitors for treating dyslipidaemia: buttressing the gaps in coronary prevention. Expert Opin Emerg Drugs. 2015, 20:299-312.
142. Thompson G.R., Catapano A., Saheb S., Atassi-Dumont M., Barbir M., Eriksson M., et al. Severe hypercholesterolaemia: Therapeutic goals and elegibility criteria for LDL apheresis in Europe. Curr Opin Lipidol. 2010, 492-498.
143. Harada-Shiba M., Arai H., Oikawa S., Ohta T., Okada T., Okamura T., et al. Guidelines for the management of familial hypercholesterolemia. J Atheroscler Thromb. 2012, 19:1043-1060.
144. Stefanutti C., Julius U. Lipoprotein apheresis: State of the art and novelties. Atheroscler Suppl. 2013, 14:19-27.
145. Thompson G.R., Maher V.M., Matthews S., Kitano Y., Neuwirth C., Shortt M.B., et al. Familial Hypercholesterolaemia Regression Study (LAARS): A randomized trial of low density-lipoprotein apheresis. Lancet. 1995, 345:811-816.
146. Sachais B.S., Katz J., Ross J., Rader D.J. Long-term effects of LDL apheresis in patients with severe hypercholesterolemia. J Clin Apher. 2005, 20:252-255.
147. Schuff-Werner P., Fenger S., Kohlschein P. Role of lipid apheresis in changing times. Clin Res Cardiol Suppl. 2007, 7:7-14.
148. Szczepiorkowski Z.M., Winters J.L., Bandarenko N., Kim H.C., Linenberg M.L., Marques M.B., et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher. 2010, 25:83.
149. Thompson G.R., Barbir M., Davies D., Dobral P., Gesinde M., Livingston M., et al. Recommendations for the use of LDL apheresis. Atherosclerosis. 2008, 98:247-255.
150. Goldberg A.C., Hopkins P.N., Toth P.P., Ballantyne C.M., Rader D.J., Robinson J.G., et al. National Lipid Association Expert Panel on Familial Hypercholesterolemia. Familial hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patient: Cliniical guidance from the National Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011, 5:S1-S8.
151. Teruel J.L., Lasuncion M.A., Navarro J.F., Carrero P., Oportuno J. Pregnancy in a patient withhomozygous familial hypercholesterolemia undergoing low-density lipoprotein apheresis by dextran sulfate adsorption. Metabolism. 1995, 44:929-933.
152. Fernández-Fuertes L.F., Tapia Martin M., Nieves Plá I., Novoa Mogollón F.J., Diaz Cremades J. Low-density lipoprotein apheresis using double filtration plasmapheresis: 27-months use in a child with homozygous familial hypercholesterolemia. Ther Apher Dial. 2010, 23:819-826.
153. Arbona C., Martinez-Hervás S., Goterris R., Montoro JReal J.T., Ascaso J.F. Low-density lipoprotein apheresis in familial hypercholesterolemia resistant to intensive medical treatment. Med Clin. 2013, 140:207-210.
154. Malatack J.J. Liver transplantation as treatment for familial homozygous hypercholesterolemia: Too early or too late. Pediatr Transplant. 2011, 15:123-125.
155. Buchwald H., Varco R.L., Matts J.P., Long J.M., Fitch L.L., Campbell G.S., et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med. 1990, 323:946-955.
156. Bilheimer D.W., Goldstein J.L., Grundy S.M., Brown S.M., Brown M.S. Reduction in cholesterol and low density lipoprotein synthesis after portacaval shunt surgery in a patient with homozygous familial hypercholesterolemia. J Clin Invest. 1975, 56:1420-1430.
157. Adolescents EP on IG for CH and RR in CA. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report. Pediatrics. 2011; 128(Supplement 5):S213-56.
158. Juonala M., Viikari J.S.A., Rönnemaa T., Marniemi J., Jula A., Loo B.-M., et al. Associations of Dyslipidemias From Childhood to Adulthood With Carotid Intima-Media Thickness, Elasticity, and Brachial Flow-Mediated Dilatation in Adulthood: The Cardiovascular Risk in Young Finns Study. Arterioscler Thromb Vasc Biol. 2008, 28:1012-1017.
159. Mahoney L.T., Burns T.L., Stanford W., Thompson B.H., Witt J.D., Rost C.A., et al. Coronary risk factors measured in childhood and young adult life are associated with coronary artery calcification in young adults: The muscatine study. J Am Coll Cardiol. 1996, 27:277-284.
160. Li S., Chen W., Srinivasan S., Bond M., Tanq R., Urbina E., et al. Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study. JAMA. 2003, 17:2271-2276.
161. Kwiterovich P.O. Recognition and management of dyslipidemia in children and adolescents. J Clin Endocrinol Metab. 2008, 93:4200-4209.
162. Rodenburg J, Vissers MN, Wiegman A, Trotsenburg ASP van, Graaf A van der, Groot E de, et al. Statin treatment in children with familial hypercholesterolemia the younger, the better. Circulation. 2007; 116:664-8.
163. Araujo M, Casavalle P, Tonietti M, editores. Consenso sobre manejo de las dislipidemias en pediatría. Arch Argent Pediatr. 2015; 113:177-86.
164. Hauk L. NHLBI Expert Panel Releases Guidelines for Cardiovascular Health and Risk Reduction in Children. Am Fam Physician. 2012, 86:776-781.
165. Daniels S.R., Gidding S.S., de Ferranti S.D. National Lipid Association Expert Panel on Familial Hypercholesterolemia. Pediatric aspects of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011, 5(Suppl 3):S30-S37.
166. Wald D.S., Bestwick J.P., Wald N.J. Child-parent screening for familial hypercholesterolemia. British Med J. 2007, 335:599.
167. Raal F.J., Santos R. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis. 2012, 223:262-268.
168. Vuorio A., Docherty K.F., Humphries S.E., Kuoppala J., Kovanen P.T. Statin treatment of children with familial hypercholesterolemia - Trying to balance incomplete evidence of long-term safety and clinical accountability: Are we approaching a consensus?. Atherosclerosis. 2013, 226:315-320.
169. Avis H.J., Hutten B.A., Gagné C., Langslet G., McCrindle B.W., Wiegman A., et al. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J Am Coll Cardiol. 2010, 55:1121-1126.
170. Vuorio A., Kuoppala J., Kovanen P.T., Humphries S.E., Tonstad S., Wiegman A., et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev. 2014, 7:CD006401.
171. Rodenburg J., Vissers M.N., Wiegman A., Trip M.D., Bakker H.D., Kastelein J.J.P. Familial hypercholesterolemia in children. Curr Opin Lipidol. 2004, 15:405-411.
172. Valenza M., Cattaneo E. Cholesterol dysfunction in neurodegenerative diseases: is Huntington's disease in the list?. Prog Neurobiol. 2006, 80:165-176.
173. Dietschy J.M., Turley S.D. Thematic review series: brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res. 2004, 45:1375-1397.
174. Miron V.E., Zehntner S.P., Kuhlmann T., Ludwin S.K., Owens T., Kennedy T.E., et al. Statin therapy inhibits remyelination in the central nervous system. Am J Pathol. 2009, 174:1880-1890.
175. Ros E., Laguna J.C. Tratamiento de la hipertrigliceridemia: fibratos frente a ácidos grasos omega-3. Rev Esp Cardiol. 2006, 6(Supl.D):52-61.
176. Van der Graaf A., Cuffie-Jackson C., Vissers M.N., Trip M.D., Gagné C., Shi G., et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J Am Coll Cardiol. 2008, 52:1421-1429.
177. Daniels S.R., Greer F.R. Lipid Screening and Cardiovascular Health in Childhood. Pediatrics. 2008, 122:198-208.
178. NICE clinical guideline 71. Identification and management of familial hypercholesterolaemia. guidance.nice.org.uk/cg71. 1-45.
179. Descamps O.S., Tenoutasse S., Stephenne X., Gies I., Beauloye V., Lebrethon M.C., et al. Management of familial hypercholesterolemia in children and young adults: Consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization. Atherosclerosis. 2011, 218:272-280.
180. Rutherford J.D. Maternal Heterozygous Familial Hypercholesterolemia and Its Consequences for Mother and Child. Circulation. 2011, 124:1599-1601.
181. Genest J., McPherson R., Frohlich J., Brophy J., Carpentier A., Couture P., et al. CCS Guidelines and position statements canadian cardiovascular society position statement on familial hypercholesterolemia. Canad J Cardiol. 2014, 30:1471-1481.
182. Kusters D.M., Hutten B.A., Twickler T.M., Avis H.J., Van der Post J.A., Stroes E.S., et al. Review: Dilemmas in treatment of women with familial hypercholesterolaemia during pregnancy. J Med. 2010, 68:299-303.
183. Jellinger P.S., Smith D.A., Mehta A.E., Ganda O., Mandelsman Y., Rodbard H.W., et al. AACE: Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr Pract. 2012, 18(suppl 1):1-78.
184. Toleikyte I., Retterstol K., Leren T.P., Iversen P.O. Pregnancy outcomes in familial hypercholesterolemia: a registry-based study. Circulation. 2011, 124:1606-1614.
185. Akl C.F., Nassar A.H. Pregnancy in a Woman with Homozygous Familial Hypercholesterolemia Not on Low-Density Lipoprotein Apheresis. Am J Perinatol Rep. 2012, 2:33-36.
186. Thorogood M., Seed M., De Mott K. Management of fertility in women with familial hypercholesterolaemia: summary of NICE guidance. BJOG. 2009, 116:478-479.
187. Eapen D.J., Valiani K., Reddy J. Management of familial hypercholesterolemia during pregnancy: Case series and discussion. J Clinical Lipidology. 2012, 6:88-91.
188. Napoli C., Glass C.K., Witztum J.L., Deutsch R., D'Armiento F.P. Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study. Lancet. 1999, 354:1234-1241.
189. Bilen O., Pokharel Y., Ballantyne C.M. Genetic testing in Hyperlipidemia. Cardiol Clin. 2015, 33:267-275.
190. Palacios L., Grandoso L., Cuevas N., Olano-Martin E., Martinez A., Tejedor D., et al. Molecular characterization of familialhypercholesterolemia in Spain. Atherosclerosis. 2012, 221:137-142.
191. Perez de Isla L., Alonso R., Watts G.F., Mata N., Cerezo A.S., Muñiz O., et al. Attainment of LDL-Cholesterol treatment goals in patients with familial hyperchoelsterolemia. JACC. 2016, 67:1278-1285.